peptide mapping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-26. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
It was never resolved. By the close of the 1960s, the US and the UK had turbofans with bypass ratios of 4 or 5 to 1. The first Soviet large turbofan, the Lotarev D-18T, did not appear before the mid-1980s. The Soloviev D-30, originally intended for the Il-86, was the most advanced Soviet civil aeroengine. It had a bypass ratio of 2.4 to 1 and aerodynamic clamshell thrust reversers. It failed to attain the required thrust, however: "only after the lapse of three years that were spent on preparing the advanced development project did it become clear that these engines would not provide the necessary take-off performance." The less-advanced Kuznetsov NK-8 series engine, adopted on March 26, 1975, had a bypass ratio of 1.15 to 1 and drag-inducing grilles over its cascade thrust reversers. Both these engines had high specific fuel consumptions and were noisy. Being ultimate developments of smaller engines, they could not offer growth to future Il-86s. The appropriate/intermediate technology principles to which most Soviet airliners before the Il-86 had been designed meant that they had typically five-member flight crews. The design and entry into service in 1972 of the Tu-154, an airliner built to high technology principles (more automation, less human input), showed that Soviet science lagged behind in the development of avionics which would remove the need for navigators and radio operators. A programme of avionics development was mounted to enable the Il-86 to operate in most weather with a three-member flight crew, matching Western technology of the time.
== Significance of work == But for Eugene Garfield's 1986 tribute to De in Current Contents, De's great contributions to cholera research would have remained unknown to many even in India. A special issue of the journal Current Science was published in 1990 in his honour, to which several eminent scientists of national and international repute contributed. In the words of Dr S Sriramachari, former director of the Institute of Pathology and additional director general of the Indian Council of Medical Research, New Delhi, De's contributions stand out as a pinnacle of excellence in our understanding of the pathogenesis of cholera. Nobel laureate Prof. Joshua Lederberg had nominated De for the Nobel Prize more than once. Said Lederberg, "our appreciation of De must then extend beyond the humanitarian consequences of his discovery. . . he is also an examplar and inspiration for a boldness of challenge to the established wisdom, a style of thought that should be more aggressively taught by example as well as precept.” De was never elected a fellow of any Indian academy and never received any major award. Indeed as Professor Padmanabhan Balaram pointed out in an editorial in Current Science, "De died in 1985 unhonoured and unsung in India's scientific circles. That De received no major award in India during his lifetime and our Academies did not see it fit to elect him to their Fellowships must rank as one of the most glaring omissions of our time.
The vascular network within the islets resembles a glomeruli-like structure, consisting of highly fenestrated endothelial cells positioned closely to each endocrine cell. Consequently, the oxygen tension within pancreatic islets is significantly higher than that in the surrounding exocrine tissue.
Comecon Frascati Manual German Marshall Fund Good laboratory practice International organisations in Europe International Transport Forum List of country groupings List of multilateral free trade agreements Marshall Plan OECD Anti-Bribery Convention OECD Better Life Index OECD Environmental Performance Reviews OECD Working Party on SMEs and Entrepreneurship Official development assistance Organization for Security and Co-operation in Europe Transfer pricing
Metal ions are common cofactors. The study of these cofactors falls under the area of bioinorganic chemistry. In nutrition, the list of essential trace elements reflects their role as cofactors. In humans this list commonly includes iron, magnesium, manganese, cobalt, copper, zinc, and molybdenum. Although chromium deficiency causes impaired glucose tolerance, no human enzyme that uses this metal as a cofactor has been identified. Iodine is also an essential trace element, but this element is used as part of the structure of thyroid hormones rather than as an enzyme cofactor. Calcium is another special case, in that it is required as a component of the human diet, and it is needed for the full activity of many enzymes, such as nitric oxide synthase, protein phosphatases, and adenylate kinase, but calcium activates these enzymes in allosteric regulation, often binding to these enzymes in a complex with calmodulin. Calcium is, therefore, a cell signaling ion, and not usually considered a cofactor of the enzymes it regulates. Other organisms require additional metals as enzyme cofactors, such as vanadium in the nitrogenase of the nitrogen-fixing bacteria of the genus Azotobacter, tungsten in the aldehyde ferredoxin oxidoreductase of the thermophilic archaean Pyrococcus furiosus, and even cadmium in the carbonic anhydrase from the marine diatom Thalassiosira weissflogii. In many cases, the cofactor includes both an inorganic and organic component. One diverse set of examples is the heme proteins, which consist of a porphyrin ring coordinated to iron.
Sources: en.wikipedia.org
In biochemistry, a Ramachandran plot (also known as a Rama plot, a Ramachandran diagram or a [φ,ψ] plot), originally developed in 1963 by G. N. Ramachandran, C. Ramakrishnan, and V. Sasisekharan, is a way to visualize energetically allowed regions for backbone dihedral angles (also called as torsional angles, phi and psi angles) φ against ψ of amino acid residues in protein structure. The figure on the left illustrates the definition of the φ and ψ backbone dihedral angles (called φ and φ' by Ramachandran). The ω angle at the peptide bond is normally 180°, since the partial-double-bond character keeps the peptide bond planar. The figure in the top right shows the allowed φ,ψ backbone conformational regions from the Ramachandran et al. 1963 and 1968 hard-sphere calculations: full radius in solid outline, reduced radius in dashed, and relaxed tau (N-Cα-C) angle in dotted lines. Because dihedral angle values are circular and 0° is the same as 360°, the edges of the Ramachandran plot "wrap" right-to-left and bottom-to-top. For instance, the small strip of allowed values along the lower-left edge of the plot are a continuation of the large, extended-chain region at upper left.
== Treatment == Treatment involves medications to suppress the immune system, including prednisone and cyclophosphamide. When present, underlying hepatitis B virus infection should be immediately treated. In some cases, methotrexate or leflunomide may be helpful. Some patients have entered a remission phase when a four-dose infusion of rituximab is used before the leflunomide treatment is begun. Therapy results in remissions or cures in 90% of cases. Untreated, the disease is fatal in most cases. The most serious associated conditions generally involve the kidneys and gastrointestinal tract. A fatal course usually involves gastrointestinal bleeding, infection, myocardial infarction, and/or kidney failure. In case of remission, about 60% experience relapse within five years. In cases caused by hepatitis B virus, however, recurrence rate is only around 6%.
Imidazole can also be formed in a vapor-phase reaction. The reaction occurs with formamide, ethylenediamine, and hydrogen over platinum on alumina, and it must take place between 340 and 480 °C. This forms a very pure imidazole product. The Van Leusen reaction can also be employed to form imidazoles starting from TosMIC and an aldimine. The Van Leusen Imidazole Synthesis allows the preparation of imidazoles from aldimines by reaction with tosylmethyl isocyanide (TosMIC). The reaction has later been expanded to a two-step synthesis in which the aldimine is generated in situ: the Van Leusen Three-Component Reaction (vL-3CR). Imidazolin-5-one derivatives can be synthesized from Oxazolidin-5-ones via amidification followed by dehydration. in this reaction, the Oxazolidin-5-ones were condensed with primary amines like aniline, sulfonamides etc. in the presence of various of catalysts like dry pyridine or glacial acetic acid + sodium acetate or glacial acetic acid + red brick powder to yield Imidazolin-5-one derivatives.
==== Discovery of the Redfield relaxation theory and equation ==== Redfield's original article published in the IBM Journal in 1957, and then in the first issue of Advanced Magnetic Resonance in 1965, "The Theory of Relaxation Processes" explained observations that molecules excited with RF in a magnetic field did not relax as expected in terms of classical thermodynamics but could be explained in terms of quantum physics, yielding a semi-classic explanation of nuclear spin in metals. The theory continues to be useful not only in NMR but in optics and computational quantum mechanics as well. The theory streamlined analysis of atomic relationships and explained observations that NMR scientists had not fully theorized. The theory helped explain spin temperature, rotating frame, nuclear spin relaxation, and predicted adiabatic demagnetization and remagnetization in a spin-locked state, and short correlation time.
Costunolide synthase (EC 1.14.14.150) is an enzyme with systematic name germacra-1(10),4,11(13)-trien-12-oate,NADPH:oxygen oxidoreductase (6alpha-hydroxylating). This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
=== Selenocysteine and selenomethionine === Selenocysteine, called the twenty-first amino acid, is essential for ribosome-directed protein synthesis in some organisms. More than 25 selenium-containing proteins (selenoproteins) are now known. Most selenium-dependent enzymes contain selenocysteine, which is related to cysteine analog but with selenium replacing sulfur. This amino acid is encoded in a special manner by DNA. Selenosulfides are also proposed as biochemical intermediates. Selenomethionine is a selenide-containing amino acid that also occurs naturally, but is generated by post-transcriptional modification.
=== Human use === Nitrofurazone was previously available as a prescription in the U.S., and was indicated as a topical solution, topical cream, or topical ointment for the treatment of bacterial skin infections, wounds, burns, and ulcers. It was also used as a prophylactic measure to prevent infection that could potentially result in skin graft rejection. Nitrofurazone is still very popular as a topical solution for the treatment of tonsillitis in Russia.
=== Proton transfer reaction chamber === Proton transfer reaction mass spectrometry has traditionally used drift tubes as ion traps. However, radio frequency ion funnels offer an attractive alternative, as they improve compound specific sensitivity significantly. This is due to increasing the effective reaction time and focusing the ions. The same pressure ranges are required for ion funnels and drift tubes, so the technology is not difficult to implement. Ion funnels have been shown to favor transmission of ions with high m/z.
Greater emphasis on risk management Introduces “Special Requirements” Introduces “Critical Items” Measure: Requirements conformance Measure: Delivery performance Adopt proven product development processes Eliminate “recurring corrective actions” AS9100 Revision C was released in January, 2009, with considerable delay in application of the new version in audits, largely due to the delay in the release of AS9101 Revision D and auditor training to the increased auditing rigor of that update. AS9100 Revision D (2016), Quality Management System – Requirements for Aviation, Space and Defense Organizations The update of AS9100 from revision C to D includes the full text of ISO 9001:2015. In addition to aligning the structure of the aviation, space and defense requirements to the new structure of ISO 9001:2015, the following key changes were implemented:
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.